The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.

Disclosed herein are preventing or treating a bacterial infection caused by at least one species of Gram-positive bacteria, the method comprising co-administering to a subject diagnosed with, at risk for, or exhibiting symptoms of a bacterial infection a first amount of a modified lysin polypeptide and a second amount of an antibiotic suitable for the treatment of a Gram-positive bacterial infection. Further disclosed herein are methods of augmenting the efficacy of an antibiotic or reducing the development of antibiotic resistance.

Disclosed herein are preventing or treating a bacterial infection caused by at least one species of Gram-positive bacteria, the method comprising co-administering to a subject diagnosed with, at risk for, or exhibiting symptoms of a bacterial infection a first amount of a modified lysin polypeptide and a second amount of an antibiotic suitable for the treatment of a Gram-positive bacterial infection. Further disclosed herein are methods of augmenting the efficacy of an antibiotic or reducing the development of antibiotic resistance.

Disclosed herein are preventing or treating a bacterial infection caused by at least one species of Gram-positive bacteria, the method comprising co-administering to a subject diagnosed with, at risk for, or exhibiting symptoms of a bacterial infection a first amount of a modified lysin polypeptide and a second amount of an antibiotic suitable for the treatment of a Gram-positive bacterial infection. Further disclosed herein are methods of augmenting the efficacy of an antibiotic or reducing the development of antibiotic resistance.

The present invention provides an antibacterial chemical compound, its manufacturing method and its use thereof which acts as antibacterial agents being useful for treating a disease or condition characterized by infectious disease, such as gastroenteritis and invasive non-typhoidal Salmonellosis, and also providing a new therapeutic option for patients infected by the bacteria with the resistance to antibiotics.

The present invention provides an antibacterial chemical compound, its manufacturing method and its use thereof which acts as antibacterial agents being useful for treating a disease or condition characterized by infectious disease, such as gastroenteritis and invasive non-typhoidal Salmonellosis, and also providing a new therapeutic option for patients infected by the bacteria with the resistance to antibiotics.

The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.